Gaku Nakazawa

Gaku Nakazawa

Auto-generated profile, based on publicly available information

Gaku Nakazawa

Kindai University Faculty of Medicine

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Circulation
Verified
Journal Article
Closed access
MNMasahiro Natsuaki
Masahiro Natsuaki
HWHirotoshi Watanabe
Hirotoshi Watanabe
TMTakeshi Morimoto
Takeshi Morimoto
KYKo Yamamoto
Ko Yamamoto
YOYuki Obayashi
Yuki Obayashi
TKTakeshi Kimura
Takeshi Kimura
BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in randomized trials. METHODS: We randomly assigned 6002 patients with acute coronary syndrome or high bleeding risk just before PCI either to prasugrel (3.75 mg/day) monotherapy or to DAPT with aspirin (81–100 mg/day) and prasugrel (3.75 mg/day) after loading of 20 mg of prasugrel in both groups. The coprimary end points were major bleeding (Bleeding Academic Research Consortium 3 or 5) for superiority and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke) for noninferiority with a relative 50% margin. RESULTS: The full analysis set population consisted of 5966 patients (no-aspirin group, 2984 patients; DAPT group, 2982 patients; age, 71.6±11.7 years; men, 76.6%; acute coronary syndrome, 75.0%). Within 7 days before randomization, aspirin alone, aspirin with P2Y12 inhibitor, oral anticoagulants, and intravenous heparin infusion were given in 21.3%, 6.4%, 8.9%, and 24.5%, respectively. Adherence to the protocol-specified antiplatelet therapy was 88% in both groups at 1 month. At 1 month, the no-aspirin group was not superior to the DAPT group for the coprimary bleeding end point (4.47% and 4.71%; hazard ratio, 0.95 [95% CI, 0.75–1.20]; P superiority =0.66). The no-aspirin group was noninferior to the DAPT group for the coprimary cardiovascular end point (4.12% and 3.69%; hazard ratio, 1.12 [95% CI, 0.87–1.45]; P non inferiority =0.01). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. There was an excess of any unplanned coronary revascularization (1.05% and 0.57%; hazard ratio, 1.83 [95%CI, 1.01–3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) in the no-aspirin group compared with the DAPT group. CONCLUSIONS: The aspirin-free strategy using low-dose prasugrel compared with the DAPT strategy failed to attest superiority for major bleeding within 1 month after PCI but was noninferior for cardiovascular events within 1 month after PCI. However, the aspirin-free strategy was associated with a signal suggesting an excess of coronary events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04609111.

3 May 2024 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
JNJagat Narula
Jagat Narula
TSThomas D Stuckey
Thomas D Stuckey
GNGaku Nakazawa
Gaku Nakazawa
AAAmir Ahmadi
Amir Ahmadi
MMMitsuaki Matsumura
Mitsuaki Matsumura
AMAkiko Maehara
Akiko Maehara
Coronary computed tomography angiography provides non-invasive assessment of coronary stenosis severity and flow impairment. Automated artificial intelligence (AI) analysis may assist in precise quantification and characterization of coronary atherosclerosis, enabling patient-specific risk determination and management strategies. This multicentre international study compared an automated deep learning-based method for segmenting coronary atherosclerosis in coronary computed tomography angiography (CCTA) against the reference standard of intravascular ultrasound (IVUS). The study included clinically stable patients with known coronary artery disease from 15 centres in the USA and Japan. An AI-enabled plaque analysis was utilized to quantify and characterize total plaque (TPV), vessel, lumen, calcified plaque (CP), non-calcified plaque (NCP), and low-attenuation plaque (LAP) volumes derived from CCTA and compared with IVUS measurements in a blinded, core laboratory-adjudicated fashion. In 237 patients, 432 lesions were assessed; mean lesion length was 24.5 mm, and mean IVUS-TPV was 186.0 mm3. AI-enabled plaque analysis on CCTA showed strong correlation and high accuracy when compared with IVUS; correlation coefficient, slope, and Y intercept for TPV were 0.91, 0.99, and 1.87, respectively; for CP volume 0.91, 1.05, and 5.32, respectively; and for NCP volume 0.87, 0.98, and 15.24, respectively. Bland–Altman analysis demonstrated strong agreement with little bias for these measurements. AI-enabled CCTA quantification and characterization of atherosclerosis demonstrated strong agreement with IVUS reference standard measurements. This tool may prove effective for accurate evaluation of coronary atherosclerotic burden and cardiovascular risk assessment. Matching cross-sectional, longitudinal, and 3D views of IVUS and CCTA show correlating presence of calcified and non-calcified plaque between the two imaging modalities. The table highlights plaque volume correlations for total plaque (TPV), calcified plaque (CP), and non-calcified plaque (NCP) on a per-lesion basis (n = 432). In the cross-sectional and longitudinal view, blue-coloured areas are calcified plaque and yellow-coloured areas are non-calcified plaque. In the 3D view, blue-coloured area is calcified plaque and yellow translucent-coloured area is non-calcified plaque.

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
NNNorihito Nakamura
Norihito Nakamura
STSho Torii
Sho Torii
HTHiroko Tsuchiya
Hiroko Tsuchiya
ANAkihiko Nakano
Akihiko Nakano
YOYuji Oikawa
Yuji Oikawa
GNGaku Nakazawa
Gaku Nakazawa
Background: Dialysis is an independent risk factor for in‐stent restenosis (ISR) after stent implantation in coronary arteries. However, the characteristics of ISR in patients undergoing dialysis remain unclear, as there are no histological studies evaluating the causes of this condition. The aim of the present study was to investigate the causes of ISR between patients who are undergoing dialysis and those who are not by evaluating tissues obtained from ISR lesions using directional coronary atherectomy. Methods and Results: A total of 29 ISR lesions from 29 patients included in a multicenter directional coronary atherectomy registry of 128 patients were selected for analysis and divided into a dialysis group (n=8) and a nondialysis group (n=21). Histopathological evaluation demonstrated that an in‐stent calcified nodule was a major histological characteristic of ISR lesions in the dialysis group and the prevalence of an in‐stent calcified nodule was significantly higher in the dialysis group compared with the nondialysis group (75% versus 5%, respectively; P <0.01). On the other hand, the prevalence of an in‐stent lipid‐rich plaque was significantly lower in the dialysis group compared with the nondialysis group (0% versus 43%, respectively; P =0.03). In all cases with an in‐stent calcified nodule, the underlying calcification before stent implantation was moderate to severe. When tissue characteristics were stratified according to duration post–stent implantation, an in‐stent calcified nodule in the dialysis group was mainly observed within 1 year after stent implantation. Conclusions: In‐stent calcified nodules are a common cause of ISR in patients undergoing dialysis and are observed within 1 year after stent implantation, suggesting different causes of ISR between patients undergoing dialysis and those who are not.

1 July 2008 in Herz
Verified
Journal Article
Closed access
PDF file
PLPeter A. Lanzer
Peter A. Lanzer
KSKatrin Sternberg
Katrin Sternberg
KSKylie Marie Schmitz
Kylie Marie Schmitz
FKFrank Kolodgie
Frank Kolodgie
GNGaku Nakazawa
Gaku Nakazawa
RVRenu Virmani
Renu Virmani

1 July 2008 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
AFAloke V. Finn
Aloke V. Finn
GNGaku Nakazawa
Gaku Nakazawa
ELElena Ladich
Elena Ladich
FKFrank D. Kolodgie
Frank D. Kolodgie
RVRenu Virmani
Renu Virmani

1 August 2025 in European Heart Journal
Verified
Journal Article
Open access
TKTomohiro Kaneko
Tomohiro Kaneko
NKNobuyuki Kagiyama
Nobuyuki Kagiyama
SOShinya Okazaki
Shinya Okazaki
MAMasashi Amano
Masashi Amano
YSYukio Sato
Yukio Sato
KHKentaro Hayashida
Kentaro Hayashida
Background and Aims: Atrial functional mitral regurgitation (AFMR) commonly affects elderly and frail individuals. The prognostic impact of transcatheter edge-to-edge repair (TEER) for AFMR has not been investigated. Methods: Patients with AFMR who underwent TEER were selected from the OCEAN-Mitral registry, and medically managed controls were selected from the REVEAL-AFMR registry, using an identical AFMR definition. The primary endpoint was a composite of all-cause mortality and heart failure hospitalization. The secondary endpoint was all-cause mortality. Results: A total of 1081 patients (mean age 80.1 ± 8.2 years, 60.5% female) with moderate or severe AFMR were included, of whom 441 underwent TEER and 640 remained on medical treatment. Overlap weighting based on the propensity score yielded well-balanced characteristics (n = 441 vs 640; all standardized mean differences <0.01), where TEER was associated with a lower incidence of the primary (hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.43–0.99, P = .044) and secondary endpoints (HR 0.58, 95% CI 0.35–0.99, P = .044). In an exploratory subgroup analysis, favourable outcomes might be pronounced in patients with ≤mild residual AFMR after TEER, while event rates in those with ≥ moderate residual AFMR were comparable with the medication group. As sensitivity analyses, inverse probability of treatment weighting (n = 158 vs 173), propensity score matching (n = 104 vs 104), and multivariable Cox regression (n = 441 vs. 640) all confirmed favourable associations of TEER with both endpoints. Conclusions: In real-world data, TEER for patients with moderate or severe AFMR were associated with a lower incidence of adverse events compared with medical treatment.